Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

e American Society for Therapeutic Radiology and Oncology's Annual Meeting on November 2, 2009 reporting on 48 month survival data in "BEST", a randomized 4-arm trial of nimotuzumab with radiation and chemoradiation with patients with locally advanced head and neck cancer. Scientific Session D: Head and Neck I - Advances in Targeted Biologic Therapy, 11:20a.m., Room W184.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differen
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... ROCHESTER, N.Y. , Dec. 12, 2014 ... engaged in the discovery and development of ... neurodegenerative diseases, today announced publication of a ... microglia, and inhibits remyelination in neurodegenerative disease" ... journal Neurobiology of Disease*.  The publication highlights ...
(Date:12/12/2014)... 11, 2014 Graphite Metallizing Corporation, the ... pumps and process equipment, has appointed Kirk Staller as ... Ontario, Canada. Staller holds a B.S. degree from Purdue ... industrial market place, much of it with a manufacturer ... his Michigan office. , “We are pleased ...
(Date:12/12/2014)... Two healthcare IT companies and a biotech ... at the Science Center’s Port business incubator. ... coworking space and Smart Activities of Daily Living is ... occupying an office at the Hubert J. P. Schoemaker ... Denovo Health, LLC. is an engagement platform targeting chronic ...
Breaking Biology Technology:Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Kirk Staller Joins Graphite Metallizing Corporation 2New Residents of Science Center’s Port Incubator Focus on Health IT and Cancer Treatment 2New Residents of Science Center’s Port Incubator Focus on Health IT and Cancer Treatment 3
... AMSTERDAM , July 29, 2010 ... Versartis, Inc.,following the recent initiation of a Phase 1 clinical trial in ... less than 12 months since the parties entered into a strategic,partnership to ... , , ...
... , CARLSBAD, Calif. , July 29 Isis Pharmaceuticals, Inc. ... million milestone payment from GlaxoSmithKline (NYSE: GSK ) related to ... rare and serious disease.  Isis will develop the drug to Phase 2 proof-of-concept, ... , , ...
... Bioengineers at the University of California, San Diego and ... wireless telemetry system that continuously monitors tissue glucose and ... published in the July 28, 2010 issue of the ... of this glucose-sensing device as an implant in animals ...
Cached Biology Technology:SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials 2SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials 3Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 2Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 3Implanted glucose sensor works for more than 1 year 2Implanted glucose sensor works for more than 1 year 3Implanted glucose sensor works for more than 1 year 4
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... hair color to the ancestral line of parasitic bacteria, scientists ... also revealed where you lived or who you spent time ... and how to look. Stanford researchers with collaborators at ... a window to the past using a technique called "reverse ...
... has finally put to rest a 90-year-old mystery that ... a child,s escape from the firing squad. Genomic analysis ... in cooperation with Institutions of Russian Academy of ... have confirmed that human remains found in the Ural ...
... Spanish . , The wide-ranging IPY findings ... researchers in more than 60 countries. Launched in March 2007, ... allow for observations during the alternate seasons in both polar ... efforts to better monitor and understand the Arctic and Antarctic ...
Cached Biology News:Reversing ecology reveals ancient environments 2UMMS researchers publish DNA identification of czar's children 2UMMS researchers publish DNA identification of czar's children 3UMMS researchers publish DNA identification of czar's children 4Polar research reveals new evidence of global environmental change 2Polar research reveals new evidence of global environmental change 3
... 'Agilents GeneSpring Workgroup solution is ... managing and mining expression data in ... and is deployed in over 40 ... research organizations worldwide. GeneSpring Workgroup streamlines ...
... a genome-wide microRNA (miRNA) expression profiling service ... which enable highly sensitive and specific direct ... arrays for mature miRNA of all species ... Sanger miRBase database (Release 8.2). Our service ...
... Proteomic Imaging System, Basic Package Superior ... Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... system for both proteomic and general life ... flexibility, enabling the use of all dyes ...
... are custom designed to meet your needs. ... 8,455 features per array (2 arrays/1" x ... array (1 array/slide). Features ... - This extended length delivers higher sensitivity ...
Biology Products: